Search Results - clinical+and+disease+specializations+%3e+diabetes

13 Results

Sort By:

Oral Delivery of Biologics Using Ingestible Microinjectors

Technology Description· Researchers at Johns Hopkins have developed methods for delivering oral formulations of traditionally parenteral medications (e.g., insulin, infliximab).· After oral delivery, autonomous microscale injectors are triggered by physiological cues in the intestine to steadily release macromolecular pharmaceuticals through...

Published: 9/27/2024 | Inventor(s): David Gracias, Florin Selaru, Arijit Ghosh

Keywords(s):

Category(s): Clinical and Disease Specializations > Diabetes, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Detecting diseases in subjects using extracelluar vesicles

Value Proposition:· Minimally invasive diagnostic platform that detects miRNAs within circulating cell-type-specific extracellular vesicles (EVs).· Low-cost testing platform (~20$/test) that provides rapid results (within 3h), optimized for at-home collection of blood samples.· Diverse applications across multiple disease indications,...

Published: 9/27/2024 | Inventor(s): Samarjit Das

Keywords(s):

Category(s): Clinical and Disease Specializations > Diabetes, Clinical and Disease Specializations > Obesity, Technology Classifications > Medical Devices, Technology Classifications > Diagnostics

Non-acid IP6K Inhibitors

Unmet Need Globally, in 2021, there were approximately 537 million cases of diabetes which resulted in about 6.7 million deaths and $966 billion of healthcare expenditure (IDF). About 95% of diabetes cases are type 2 diabetes (T2D), which is characterized by either impaired insulin production or insulin resistance, and primarily occurs in adults. There...

Published: 9/27/2024 | Inventor(s): Tyler Heitmann, James Barrow

Keywords(s):

Category(s): Clinical and Disease Specializations > Diabetes, Clinical and Disease Specializations > Diabetes > Type 2 Diabetes, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets

Lipid Nanoparticles as Oral Vehicles of Immunotherapy

Unmet NeedType 1 diabetes (T1D) affects 1.25 million Americans currently and by 2050, this number is expected to reach 5 million. Though a currently untreatable autoimmune disease, one of the more promising approaches has been a costimulatory blockade of malfunctioning immune cells via administration of CTLA4-Ig. However, its efficacy is impeded by...

Published: 9/27/2024 | Inventor(s): Giorgio Raimondi, Julia Patrone, Xiomara Calderon-Colon, Olivia Tiburzi

Keywords(s): Diabetes, Disease Indication, Drug Delivery Mechanism, Drug Delivery Vehicle, Immunotherapy, Metabolic Disorders, Nanoparticles, Oral Administration, Single, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Diabetes > Type 1 Diabetes, Clinical and Disease Specializations > Diabetes, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Non-invasive Diagnostic Biomarker for Pancreatic Islet Populations

Unmet NeedAffecting more than 230 million people worldwide, diabetes is a chronic disease caused by a deficiency and/or resistance to insulin. Insulin production is controlled by the pancreas, specifically by the pancreatic islets, a region of the pancreas that contains the hormone-producing cells. The pancreatic islets are made up of at least 5 different...

Published: 9/26/2024 | Inventor(s): Richard Edden, Eric Porges, Damon Lamb, Martha Thompson

Keywords(s): Biomarker, Clinical Diagnostics, Diabetes, Diagnostic Biomarker, Disease Indication, Image Processing Software, Imaging and Sensing Systems, In Vitro Diagnostics, In Vivo Medical Imaging, Metabolic Disorders

Hepatic Kisspeptin Secretion Impairs Insulin Secretion from Pancreatic Bets Cell. Kisspeptin Receptor GPR54 Antagonist for Treatment of Prediabetes and Diabetes Mellitus in Humans.

Unmet NeedGlucagon and insulin work together to keep blood glucose levels balanced. Glucagon stimulates the liver to secrete glucose while insulin suppresses glucose release. If the body does not regulate glucose levels properly, Type 2 diabetes mellitus (T2DM) will develop. Type 2 diabetes mellitus is a world-wide epidemic, projected to affect 1/3...

Published: 9/26/2024 | Inventor(s): Woo-Jin Song, Prosenjit Mondal, Mehboob Hussain

Keywords(s): Biomarker, Diabetes, Disease Indication, Mechanism-of-action Biomarker, Metabolic Disorders, Therapeutic Matter, Therapeutics, Type 2 Diabetes, Type II Diabetes

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Metabolic Diseases, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Diabetes, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Diabetes > Type 2 Diabetes

Methods and Kits for Identifying Autoreactive Lymphocytes in Type 1 Diabetes and Other Autoimmune Disease

Unmet NeedAutoreactive lymphocytes contribute to the pathogenesis of autoimmune diseases including, type 1 diabetes, multiple sclerosis, and systemic lupus erythematosus (SLE). One of the challenges in studying these populations of lymphocytes, also known as X- cells, is that there are no biomarkers to distinguish them from protective T cells and B...

Published: 9/26/2024 | Inventor(s): Abdel Rahim Hamad, Thomas Donner, Rizwan Ahmed, Zahra Omidian

Keywords(s): Biomarker, Clinical Diagnostics, Diabetes, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Metabolic Disorders

An Insulin-loaded Nanoparticle and the Method for Preparing Thereof

Unmet Need:Repeated injections of insulin is the standard of care for treating Type 1 diabetes, and essential for control and management of Type 2 diabetes. Drawbacks of this treatment include poor patient compliance, discomfort, and an impaired lifestyle, and hypoglycemia. Oral administration of insulin, if successful, could deliver insulin such that...

Published: 9/26/2024 | Inventor(s): Hai-Quan Mao, Jose Santos, Zhiyu He, Huahua Huang, Lixin Liu, Kam Leong, Yongming Chen

Keywords(s): Diabetes, Disease Indication, Drug Delivery Vehicle, Metabolic Disorders, Nanoparticles, Therapeutic Matter, Therapeutic Method, Therapeutics

Three-dimensional Vascular Network Assembly from Diabetic Patient-derived Induced Pluripotent Stem Cells

In diabetics, hyperglycemia results in deficient endothelial progenitors and cells, leading to cardiovascular complications. We aim to engineer three-dimensional (3D) vascular networks in synthetic hydrogels from type-1 diabetes (T1D) patient-derived human induced pluripotent stem cells (hiPSCs), thus serving as a transformative autologous vascular...

Published: 9/26/2024 | Inventor(s): Sharon Gerecht, Xin Yi Chan, Quinton Smith, Yu-I Shen

Keywords(s): Biologics, Cell Model, Diabetes, Discovery/Research Tools, Disease Indication, In Vitro Research Tool, Metabolic Disorders, Stem Cells, Therapeutic Matter, Therapeutic Substance, Therapeutic Substance Synthesis Method, Therapeutics, Translational Research Biomarker, Whole cell

CTD110.6 monoclonal antibody

C03770: CTD110.6 monoclonal antibody Technical Details: O-linked N-acetylglucosamine (O-GlcNAc) is a newly described but ubiquitous dynamic modification of key regulatory proteins in side virtually all multi-cellular eukaryotic cells. Recently, this sugar modification has been shown to be as abundant as protein phosphorylation, often competing with...

Published: 9/26/2024 | Inventor(s): Frank Comer, Gerald Hart

Keywords(s): Alzheimer's Disease, Antibodies, Biologics, Cancers, CNS and Neurological Disorders, Diabetes, Discovery/Research Tools, Disease Indication, Metabolic Disorders, Monoclonal Antibodies, Research Reagent, Therapeutic Matter, Therapeutic Substance, Therapeutics, Translational Research Biomarker

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Diabetes, Clinical and Disease Specializations > Metabolic Diseases, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools > Antibodies, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities

1 2